

### **Referências Bibliográficas**

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science*. 1987;235(4785):177-82.
2. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. *J Clin Oncol*. 2002;20(3):719-26.
3. Baselga J. Phase I and II clinical trials of trastuzumab. *Ann Oncol*. 2001;12 Suppl 1:S49-55.
4. Arteaga CL. Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. *Breast Cancer Res*. 2003;5(2):96-100.
5. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *J Clin Oncol*. 2007;25(1):118-45.
6. Perry N, Puthaar E, European Commission. European guidelines for quality assurance in breast cancer screening and diagnosis. Luxembourg: Office for Official Publications of the European Communities; 2006.
7. Ellis IO. Best Practice No 176: updated recommendations for HER2 testing in the UK. *J Clin Pathol*. 2004;57(3):233-7.
8. Hanna W, O'Malley FP, Barnes P, Berendt R, Gaboury L, Magliocco A, et al. Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer. *Curr Oncol*. 2007;14(4):149-53.
9. Albanell J, Andreu X, Calasanz MJ, Concha Á, Corominas JM, García-Caballero T, et al. Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). *Clin Transl Oncol*. 2009;11(6):363-75.
10. Middleton LP, Price KM, Puig P, Heydon LJ, Tarco E, Sneige N, et al. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. *Arch Pathol Lab Med*. 2009;133(5):775-80.
11. Wong NS, Anderson BO, Khoo KS, Ang PT, Yip CH, Lu Y-S, et al. Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009. *Lancet Oncol*. 2009;10(11):1077-85.
12. Arafah M. HER2/neu immunostaining in invasive breast cancer: analysis of false positive factors. *Oman Med J* [Internet]. 2010 [cited 2012 Sep 13]. Available from: [http://www.omjournal.org/fulltext\\_PDF.aspx?DetailsID=16&type=fulltext](http://www.omjournal.org/fulltext_PDF.aspx?DetailsID=16&type=fulltext)

13. Nizzoli R, Bozzetti C, Crafa P, Naldi N, Guazzi A, Di Blasio B, et al. Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas. *Diagn Cytopathol.* 2003;28(3):142-6.
14. Sartelet H. Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma. *J Clin Pathol.* 2005;58(8):864-71.
15. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). *Arch Pathol Lab Med.* 2010;134(7):e48-72.
16. Yildiz-Aktas IZ, Dabbs DJ, Bhargava R. The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. *Mod Pathol.* 2012;25(8):1098-105.
17. Goldstein NS, Hewitt SM, Taylor CR, Yaziji H, Hicks DG. Recommendations for improved standardization of immunohistochemistry. *Appl Immunohistochem Mol Morphol.* 2007;15(2):124-33.
18. Gómez-Martín C, Concha Á, Corominas JM, García-Caballero T, García-García E, Iglesias M, et al. Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. *Clin Transl Oncol.* 2011;13(9):636-51.
19. Khoury T, Sait S, Hwang H, Chandrasekhar R, Wilding G, Tan D, et al. Delay to formalin fixation effect on breast biomarkers. *Mod Pathol.* 2009;22(11):1457-67.
20. Moatamed NA, Nanjangud G, Pucci R, Lowe A, Shintaku IP, Shapourifar-Tehrani S, et al. Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer. *Am J Clin Pathol.* 2011;136(5):754-61.
21. Tong LC, Nelson N, Tsourigiannis J, Mulligan AM. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study. *Am J Surg Pathol.* 2011;35(4):545-52.
22. Yildiz-Aktas IZ, Dabbs DJ, Cooper KL, Chivukula M, McManus K, Bhargava R. The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. *Am J Clin Pathol.* 2012;137(5):691-8.
23. O'Leary T, Fowler C, Evers D, Mason J. Protein fixation and antigen retrieval: chemical studies. *Biotech Histochem.* 2009;84(5):217-21.
24. Thurby C, White MR, Simutis F, Gillham S, Slinker D. An improved method of tissue adhesion on glass microslides for immunohistochemical evaluation by the use of selected tissues from the dog and monkey. *J Histotechnol.* 2009;32(4):198-201.

25. Henson DE. Loss of p53-immunostaining intensity in breast cancer. *J Natl Cancer Inst.* 1996;88(15):1015-6.
26. Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. *J Natl Cancer Inst.* 1996;88(15):1054-9.
27. Manne U, Myers RB, Srivastava S, Grizzle WE. Re: Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. *J Natl Cancer Inst.* 1997;89(8):585-6.
28. Ibarra JA, Rogers LW. Fixation time does not affect expression of HER2/neu: a pilot study. *Am J Clin Pathol.* 2010;134(4):594-6.
29. Goldsmith JD, Allred DC, Beasley MB, Eisen R, Fulton RS, Gown AM, et al. Fixation time does not affect expression of HER2/neu. *Am J Clin Pathol.* 2011;135(3):484.
30. Bohn OL, Sanchez-Sosa S, Ibarra JA, Rogers LW. Fixation time and HER2/neu assessment. *Am J Clin Pathol.* 2011;135(6):979.
31. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, et al. Real-world performance of HER2 testing: national surgical adjuvant breast and bowel project experience. *J Natl Cancer Inst.* 2002;94(11):852-4.
32. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup Trial N9831. *J Natl Cancer Inst.* 2002;94(11):855-7.
33. Mayr D, Heim S, Werhan C, Zeindl-Eberhart E, Kirchner T. Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest™ (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH). *Virchows Archiv.* 2009;454(3):241-8.
34. Choritz H, Büsche G, Kreipe H. Quality assessment of HER2 testing by monitoring of positivity rates. *Virchows Archiv.* 2011;459(3):283-9.
35. Raji A. Human epidermal growth factor receptor 2 testing recommendation. *J Clin Oncol.* 2007;25(25):4020-1.
36. Hammond ME, Hayes DF, Wolff AC. Clinical notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. *J Clin Oncol.* 2011;29(15):e458.